Business Wire12d
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.
Hosted on MSN2mon
New Product Offerings Support QIAGEN's Shares Amid Currency Woes
To support internal growth, QIAGEN invests heavily in research and development (R&D) for the menu expansion of its key platforms. R&D expenditures represented 8.9% of third-quarter sales ...
Qiagen files patent infringement complaint against bioMerieux
Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...
TMCnet9d
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further ...